Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11150138 | 0.81 | EPHX2 (0.39) | ALDH1A1HTTHSD17B10MEN1KMT2A | |
| SCHEMBL22072070 | 0.80 | KDM4E (0.35) | EPHX2KDM4E | |
| Hydrochloric Acid SCHEMBL11155742 | 0.79 | EPHX2 (0.38) | ALDH1A1HTTHSD17B10MEN1KMT2A | |
| SCHEMBL5672302 | 0.79 | EPHX2 (0.56) | ALDH1A1HTTHSD17B10KMT2AEPHX2 | |
| SCHEMBL2390346 | 0.74 | HSD11B1 (0.48) | KMT2AEPHX2 | |
| SCHEMBL4101119 | 0.74 | EPHX2 (0.68) | MEN1KMT2AEPHX2 | |
| SCHEMBL11465705 | 0.73 | CYP3A4 (0.57) | ALDH1A1HTTHSD17B10MEN1KMT2A | |
| SCHEMBL3363980 | 0.72 | SMN1; SMN2 (0.63) | ALDH1A1MEN1KMT2AEPHX2SMN1; SMN2 | |
| SCHEMBL11214247 | 0.70 | MAPT (0.42) | ALDH1A1HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11449079 | 0.69 | CXCR3 (0.40) | MEN1KMT2AP2RX7SMN1; SMN2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734971-A2 | DRUG TO TREAT STIMULANT ADDICTION | Single Dose Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| WO-2025040956-A2 | DRUG TO TREAT STIMULANT ADDICTION | RAUTIOLA DAVIN (US) | 2025-02-27 | — | — | WO | claimed |
| US-11576866-B2 | Gastric residence systems for sustained delivery of adamantane-class drugs | LYNDRA THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | claimed |
| WO-2022255867-A1 | PROTEIN BIOMARKERS FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2022-12-08 | — | — | WO | claimed |
| WO-2020191503-A1 | METHODS AND USES OF BROMANTANE AND DERIVATIVES THEREOF FOR TREATING LUNG DISEASE, FATTY LIVER DISEASE, AND KIDNEY DISORDERS | ALGERNON PHARMACEUTICALS INC. (CA) | 2020-10-01 | — | — | WO | claimed |
| WO-2026107393-A2 | AAV CAPSID MODIFICATIONS THAT REDUCE IMMUNOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4734971-A2 | DRUG TO TREAT STIMULANT ADDICTION | Single Dose Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4734971-A2 | DRUG TO TREAT STIMULANT ADDICTION | Single Dose Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12618082-B2 | Engineered muscle targeting compositions | THE BROAD INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | disclosed |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| WO-2011001258-A1 | COMPOSITIONS, METHODS, AND KITS FOR TREATING VIRAL AND BACTERIAL INFECTIONS BY TOCOTRIENOLS, TOCOMONOENOLS, TOCODIENOLS, TOCOPHEROLS, AND THEIR DERIVATES | EVITA LIFE SCIENCE PTE. LTD (SG) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| US-20070233401-A1 | Spectral measurement with assisted data analysis | THERMO ELECTRON SCIENTIFIC INSTRUMENTS LLC | 2007-10-04 | — | — | US | disclosed |
| WO-2007109188-A2 | SPECTRAL MEASUREMENT WITH ASSISTED DATA ANALYSIS | THERMO ELECTRON SCIENTIFIC INSTRUMENTS LLC (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618082-B2 | Engineered muscle targeting compositions | MUSK, MYO3B, MYOF | ALDH1A1 4196/4885HTT 3774/4885HSD17B10 3487/4885 |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | ALDH1A1 3571/4885HTT 3/4885HSD17B10 1538/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | ALDH1A1 756/4885HTT 622/4885HSD17B10 804/4885 |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | ALDH1A1 1992/4885HTT 2121/4885HSD17B10 3762/4885 |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | FLNB, FLNA, DAGLB | ALDH1A1 3021/4885HTT 4053/4885HSD17B10 1745/4885 |
| US-11576866-B2 | Gastric residence systems for sustained delivery of adamantane-class drugs | SLC6A2, SLC10A2, SLC18A2 | ALDH1A1 242/4885HTT 1552/4885HSD17B10 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.